Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Semaglutide is a GLP-1 analogue suitable for once-weekly administration, and is in development for the treatment of T2D
At the World Economic Forum in Davos in January, Chinese Premier Li Qiang sought to assuage such concerns, saying China is open for business, and that there is plenty of potential for foreign investment
"..." more
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
Verdict at a Glance Orforglipron represents a potential paradigm shift as the first oral non-peptide GLP-1 agonist without fasting restrictions, and it demonstrated superiority over oral semaglutide in the head-to-head ACHIEVE-3 trial for both HbA1c and weight loss
US$ 24.30
US$ 21.49
US$ 28.69
US$ 26.36
US$ 23.62
US$ 23.90
US$ 25.40
